Thu, Oct 2, 2014, 6:09 AM EDT - U.S. Markets open in 3 hrs 21 mins

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • ccharles792 ccharles792 Jul 11, 2013 3:58 PM Flag

    Just the beginning... read

    Been on Cruise with No Internet ( Help ) Catching Up -- I Like This.
    Article : Two Biotech Stocks That Could Soon be Aquired
    This fact makes Celldex Therapeutics (NASDAQ: CLDX) especially attractive. The company has a breast cancer drug, CDX-011, that significantly increased survival in a population of seriously ill patients. This drug has been the basis for its 200% one-year gain, as it specifically targets an expression called GPNMB, and solidifies Celldex as a legitimate player in immunotherapy.

    Then, the company has a Phase 3 drug, Rindopepimut, that treats brain cancer, and has shown consistent benefit in treating patients in three different Phase 2 studies. Moreover, the company has six products in clinical studies, all in treating cancer, making it a legitimate contender in the fight against cancer.

    What makes Celldex attractive, aside from its pipeline, is the fact that it has been very successful at developing treatment regiments that maximize the immune system via targeted therapies, antibodies, and immune system modifiers. Its two late stage products, CDX-011 and Rindopepimut, have peak sales potential of $700 million and $500 million respectively; about equal to its current market capitalization.

    When we try to find a potential suitor, you realize that it could be a dozen different companies. Celldex could create several approved products and billions in sales within the next five years. Roche, Merck, Amgen, Bristol-Myers, Johnson & Johnson, or just about any large pharma with an oncology program. If you considerthat Celldex is trading at just one times peak sales – and the average acquisition is 3-4 times peak sales – you can see that Celldex could become attractive very quickly.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "What makes Celldex attractive, aside from its pipeline, is the fact that it has been very successful at developing treatment regiments that maximize the immune system via targeted therapies, antibodies, and
      immune system modifiers. Its two late stage products, CDX-011 and Rindopepimut, have peak sales potential of $700 million and $500 million respectively; about equal to its current market capitalization."

      Yes, but was is left out if the multiple/numerous other indicators that mid to high GPNMB can does and (CLDX will and with partnerships perhaps on some indications target and Rindo has equally high diversification, company pursuing rarest indications first to bring the goose to market. So when we are talking potential peak sales for other applications to be dutifully and responsibly targeted those numbers more than quadruple

 
CLDX
12.37-0.59(-4.55%)Oct 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.